

UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

ASSISTANT SECRETARY AND COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

COPY MAILED

JUL 0 7 1999

SPECIAL PROGRAMS OFFICE DAC FOR PATENTS

: DECISION ACCORDING STATUS : UNDER 37 CFR 1.47(a)

D. Byron Miller
ALZA Corporation
950 Page Mill Road
Palo Alto, CA 94303-0802

In re Application of Cormier, Sendelbeck, Muchnik and Leung Application No. 09/190,887 Filed: November 12, 1998 For: BUFFERED DRUG FORMULATIONS FOR TRANSDERMAL ELECTROTRANSPORT DELIVERY

This is in response to the "Petition Under 37 CFR 1.47(a)," filed November 12, 1998.

The petition is granted.

The above-identified application was filed on November 12, 1998, with a declaration signed by Michel Cormier, Sara Sendelbeck and Anna Muchnik on behalf of themselves and non-signing inventor, Iris Leung.

The petition filed November 12, 1998, was accompanied by a declaration of facts of Mr. Byron Miller and exhibits, which include a copy of an ALZA company/employee newsletter; copies of all correspondence between Mr. Miller and Dr. Leung, including a letter from Dr. Leung addressed to Mr. Miller declining to sign the declaration; and a copy of Dr. Leung's Confidentiality Information, Secrecy and Invention Agreement. The declaration of facts also sets forth Dr. Leung's last known address. Petitioners have shown that the non-signing inventor, Dr. Leung, has refused to join in the filing of the above-identified application. Specifically, the declaration of facts, set forth by Mr. Miller, establishes that Dr. Leung was mailed a copy of the continuation-in-part application papers, including the specification, claims, drawings and oath or declaration, but refused to execute the declaration.

The above-identified application and papers have been reviewed and found in compliance with 37 CFR 1.47(a). This application is hereby accorded Rule 1.47(a) status.

As provided in Rule 1.47(a), this Office will forward notice of this application's filing to the non-signing inventor at the address given in the Declaration. Notice of the filing of this application will also be published in the Official Gazette.

After this decision is mailed, petitioner's deposit account No. 01-1173 will be charged the required \$130 petition fee.

Thereafter, the above-mentioned application will be returned to the Office of Initial Patent Examination for further processing as a Rule 47 application with an indication on the PALM bib-data sheet that the application has been accorded Rule 47 status.

Telephone inquiries regarding this decision should be directed to the undersigned at (703)306-5586.

Eugenia A. Jones

Legal Advisor

Special Program Law Office

Office of the Deputy Assistant Commissioner

for Patent Policy and Projects

JS



UNITED STATES DEPARTMENT OF COMMERCE

Patent and Trademark Office
ASSISTANT SECRETARY AND COMMISSIONER
OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

Dr. Iris K. Leung 14727 Greenleaf Valley Drive Chesterfield, MO 63017-5514 **COPY MAILED**

JUL 0 7 1999

In re Application of Cormier, Sendelbeck, Muchnik and Leung Application No. 09/190,887

SPECIAL PROGRAMS OFFICE DAC FOR PATENTS

Filed: November 12, 1998

For: BUFFERED DRUG FORMULATIONS FOR TRANSDERMAL ELECTROTRANSPORT DELIVERY

Dear Dr. Leung:

You are named as a joint inventor in the above identified United States patent application, filed under the provisions of 35 U.S.C. 116 (United States Code), and 37 CFR 1.47(a), Rules of Practice in Patent Cases. Should a patent be granted on the application you will be designated therein as a joint inventor.

As a named inventor you are entitled to inspect any paper in the file wrapper of the application, order copies of all or any part thereof (at a prepaid cost per 37 CFR 1.19) or make your position of record in the application. Alternatively, you may arrange to do any of the preceding through a registered patent attorney or agent presenting written authorization from you. If you care to join the application, counsel of record (see below) would presumably assist you. Joining in the application would entail the filing of an appropriate oath or declaration by you pursuant to 37 CFR 1.63.

Telephone inquiries regarding this communication should be directed to the undersigned at (703)305-9285. Requests for information regarding your application should be directed to the File Information Unit at (703)308-2733. Information regarding how to pay for and order a copy of the application, or a specific paper in the application, should be directed to Certification Division at (703)308-9726 or 1(800)972-6382 (Qutside the Washington D.C. area).

LIGIMA U. Jones Eugenia A. Jones Legal Advisor

Special Program Law Office
Office of the Deputy Assistant Commissioner
for Patent Policy and Projects

D. BYRON MILLER
ALZA CORPORATION
950 PAGE MILL ROAD
PALO ALTO, CA 94303-0802